Propanc Biopharma, Inc. (PPCB)Healthcare | Biotechnology | Camberwell, Australia | NasdaqCM
1.60 USD
-0.01
(-0.621%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.56 -0.04 (-0.040%) ⇩ (July 13, 2026, 7:31 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:41 a.m. EDT
The immediate outlook is severely clouded by a statistically weak forecast predicting a further 20% drop over the next 45 days, compounded by a massive 14-day price decline of nearly 40%. While recent headlines celebrate a $5 million buyback and clinical trial progress, these are classic 'distress sale' catalysts often followed by deeper liquidity crises rather than sustainable rebounds. The company's balance sheet is fundamentally broken, with debt significantly exceeding cash reserves and negative returns on both assets and equity, indicating that operations are destroying value. The stock has suffered a catastrophic 100% loss over the last nine years, with only a single anomalous year of recovery failing to reverse the long-term trend. With no dividend history to provide income and a precarious capital structure, this is a speculative gamble on a turnaround that the current data suggests is unlikely to materialize soon. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.122054 |
| AutoTheta | 0.196364 |
| MSTL | 0.386602 |
| AutoETS | 0.396986 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 23.61 |
| Ljung-Box p | 0.001 |
| Jarque-Bera p | 0.058 |
| Excess Kurtosis | 0.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.3 |
| Market Cap | 3,645,393 |
| Trailing P/E | 0.00 |
| Beta | 3.30 |
| Website | https://www.propanc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9892667 |
| Address1 | 302, 6 Butler Street |
| All Time High | 6,250,000,000,000.0 |
| All Time Low | 0.01 |
| Ask | 2.0 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 6,013,810 |
| Average Daily Volume3 Month | 4,027,003 |
| Average Volume | 4,027,003 |
| Average Volume10Days | 6,013,810 |
| Beta | 3.303 |
| Bid | 1.16 |
| Bid Size | 2 |
| Book Value | 11.24 |
| City | Camberwell |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.6 |
| Current Ratio | 2.366 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.63 |
| Day Low | 1.56 |
| Debt To Equity | 5.3 |
| Display Name | Propanc Biopharma |
| Dividend Date | 1,605,744,000 |
| Ebitda | -18,373,020 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.26 |
| Enterprise Value | 4,775,564 |
| Eps Trailing Twelve Months | 570.5 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 61 3 9882 9969 |
| Fifty Day Average | 1.86935 |
| Fifty Day Average Change | -0.26934993 |
| Fifty Day Average Change Percent | -0.14408748 |
| Fifty Two Week Change Percent | -98.92667 |
| Fifty Two Week High | 270.25 |
| Fifty Two Week High Change | -268.65 |
| Fifty Two Week High Change Percent | -0.99407953 |
| Fifty Two Week Low | 1.3 |
| Fifty Two Week Low Change | 0.30000007 |
| Fifty Two Week Low Change Percent | 0.23076929 |
| Fifty Two Week Range | 1.3 - 270.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,357,569,000,000 |
| Float Shares | 2,040,076 |
| Free Cashflow | 4,777,801 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14848 |
| Held Percent Institutions | 0.008119999 |
| Implied Shares Outstanding | 2,278,371 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-08-15 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,779,062,400 |
| Last Split Factor | 1:25 |
| Long Business Summary | Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia. |
| Long Name | Propanc Biopharma, Inc. |
| Market | us_market |
| Market Cap | 3,645,393 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_134729532 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -19,293,176 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 3,690,961 |
| Open | 1.5717 |
| Operating Cashflow | -4,172,839 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 61 3 9882 0780 |
| Post Market Change | -0.04000008 |
| Post Market Change Percent | -2.500005 |
| Post Market Price | 1.56 |
| Post Market Time | 1,783,985,511 |
| Previous Close | 1.61 |
| Price Hint | 4 |
| Price To Book | 0.14234877 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.131 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.621117 |
| Regular Market Day High | 1.63 |
| Regular Market Day Low | 1.56 |
| Regular Market Day Range | 1.56 - 1.63 |
| Regular Market Open | 1.5717 |
| Regular Market Previous Close | 1.61 |
| Regular Market Price | 1.6 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 93,377 |
| Return On Assets | -0.62307 |
| Return On Equity | -1.26977 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,278,371 |
| Shares Percent Shares Out | 0.0074 |
| Shares Short | 16,903 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 31,201 |
| Short Name | Propanc Biopharma, Inc. |
| Short Percent Of Float | 0.0083 |
| Short Ratio | 0.0 |
| Source Interval | 15 |
| State | VIC |
| Symbol | PPCB |
| Total Cash | 443,702 |
| Total Cash Per Share | 0.195 |
| Total Debt | 573,873 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 570.5 |
| Trailing P E | 0.0028045576 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.771162 |
| Two Hundred Day Average Change | -11.171162 |
| Two Hundred Day Average Change Percent | -0.8747177 |
| Type Disp | Equity |
| Volume | 93,377 |
| Website | https://www.propanc.com |
| Zip | 3,124 |